bugger missed the webcast! seems as though...

bugger missed the webcast! seems as though sellers/shorts/downrampers having a field day with the primary endpoint point, but looks like there is still great potential to me!

“The trial results show that rexlemestrocel-L significantly reduces cardiovascular mortality when used early in heart failure patients at risk of disease progression, and provides durable protection from heart attacks or strokes in these vulnerable patients,”

“New therapies have not materially reduced the high death rates from cardiovascular disease which is why these data have he potential to change the treatment paradigm for patients with advanced chronic heart failure.”

GLTAH. HODL!